DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Thursday. The brokerage set a “hold” rating on the stock.

A number of other equities analysts have also recently issued reports on DBVT. JMP Securities restated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research report on Tuesday, December 10th. HC Wainwright upped their price target on DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th.

DBV Technologies Stock Performance

Shares of DBV Technologies stock opened at $4.97 on Thursday. The company’s 50 day moving average price is $3.32 and its 200-day moving average price is $3.83. DBV Technologies has a 52-week low of $2.20 and a 52-week high of $9.49. The stock has a market capitalization of $102.23 million, a price-to-earnings ratio of -1.10 and a beta of 0.64.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.